IMPEDIMED LIMITED
NOTICE UNDER SECTION 708AA(2)(f) CORPORATIONS ACT 2001 (CTH)

ImpediMed Limited ABN 65 089 705 144 (ImpediMed) has announced a renounceable pro-rata entitlement offer of 1 fully paid ordinary share (New Shares) for every 9 ImpediMed ordinary shares held as at 7.00 pm (AEST) on the record date of 5 June 2009 by shareholders with registered addresses in Australia and New Zealand.

This notice is given to ASX under paragraph 708AA(2)(f) Corporations Act 2001 (Corporations Act) as modified by Australian Securities & Investments Commission class order CO 08/35.

1 ImpediMed will offer the New Shares for issue without disclosure to investors under Part 6D.2 of the Corporations Act.

2 As at the date of this notice ImpediMed has complied with the provisions of:
   (a) Chapter 2M of the Corporations Act as they apply to ImpediMed; and
   (b) section 674 of the Corporations Act.

3 As at the date of this notice there is no excluded information within the meaning of sections 708AA(8) and 708AA(9) of the Corporations Act which is required to be disclosed by ImpediMed.

4 The potential effect the issue of the New Shares (Issue) will have on the control of ImpediMed and the consequences of that effect are as follows:
   (a) if all eligible shareholders take up their entitlements under the offer, the Issue will have no significant effect on the control of the Company;
   (b) if particular eligible shareholders do not take up all of their entitlements under the offer, the shareholding interests of those eligible shareholders will be diluted;
   (c) the proportional interests of shareholders with registered addresses outside Australia and New Zealand may be diluted because those shareholders are not entitled to participate in the offer;
   (d) although the issue of New Shares to Wilson HTM Corporate Finance Ltd as underwriter of the offer may increase the shareholding interest of Wilson HTM Corporate Finance Ltd, it is not expected to have any material effect on the control of the Company;
   (e) Starfish Ventures Pty Ltd (Starfish) notified ImpediMed on 6 April 2009 that it had Voting Power in ImpediMed of 37.3%. Starfish has advised ImpediMed that any Control of ImpediMed which Starfish may have will not increase as a result of the Issue;
   (f) Based on current disclosures by other substantial shareholders, the maximum percentage shareholding of any existing shareholder (other than Starfish) after the Issue will not exceed 20%.
In this notice, the terms Control and Voting Power have the meanings given to them in the Corporations Act.

Signed for ImpediMed Limited by

Phil Auckland
CFO & Company Secretary